Skip to main content
Clinical Trials/DRKS00030723
DRKS00030723
Not yet recruiting
Not Applicable

Prospective observational cohort study on the correlation of microbiome diversity and oncological outcome in immune checkpoint inhibitor therapy - MicrobiomCheckpoint01

Rheinische Friedrich-Wilhelms-Universität Bonn0 sites100 target enrollmentNovember 11, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C00-C97
Sponsor
Rheinische Friedrich-Wilhelms-Universität Bonn
Enrollment
100
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 11, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Voluntarily agree to participate in this study, fully understand the study and sign the informed consent form (ICF).
  • \=18 years old
  • Are you planning treatment with a checkpoint inhibitor (anti\-PD\-1, anti\-PD\-L1, or anti\-CTLA\-4\) alone or in combination with another checkpoint inhibitor or treatment agent or modality (eg, B. Targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with the use of the active substance approved by the EMA/BfArM
  • Life expectancy \= 6 months
  • Willingness to provide stool samples for research purposes

Exclusion Criteria

  • Voluntarily agree to participate in this study, fully understand the study and sign the informed consent form (ICF).
  • \=18 years old
  • Are you planning treatment with a checkpoint inhibitor (anti\-PD\-1, anti\-PD\-L1, or anti\-CTLA\-4\) alone or in combination with another checkpoint inhibitor or treatment agent or modality (eg, B. Targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with the use of the active substance approved by the EMA/BfArM
  • Life expectancy \= 6 months
  • Willingness to provide stool samples for research purposes

Outcomes

Primary Outcomes

Not specified

Similar Trials